RxDoctor Payments Data

Michael Margolis, DO

Family Medicine · Hollywood, FLNPI 1346204203

Payments from drug & device makers

$10,802in general payments, 2019–2025

Across 490 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • AbbVie$949
  • GSK$919
  • AstraZeneca$848
  • Novo Nordisk$761
  • Amgen$571
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$2,08019%
  • Food & beverage$8,68880%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,802 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$63,678
Medicare patients
132
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$89,782
FarxigaDapagliflozin Propanediol77$84,731
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$64,671
OzempicSemaglutide34$51,731
JanuviaSitagliptin Phosphate17$27,461
XareltoRivaroxaban28$26,392
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$14,880
MounjaroTirzepatide15$14,220
KerendiaFinerenone18$13,302
TrulicityDulaglutide14$13,126
MyrbetriqMirabegron14$11,385
ArexvyRsvpref3 Antigen/As01e/Pf35$10,411
Janumet XrSitagliptin Phos/Metformin Hcl13$9,612
JardianceEmpagliflozin13$8,977
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix$919$96,259169 claims
AstraZenecaFarxiga, Symbicort$848$90,85295 claims
PfizerEliquis$461$89,78289 claims
Novo NordiskOzempic$761$51,73134 claims
MerckJanuvia, Janumet Xr$144$37,07330 claims
Lilly USA, LLCMounjaro, Trulicity$569$27,34629 claims
Johnson & JohnsonXarelto$131$26,39228 claims
BayerKerendia$488$13,30218 claims
Astellas Pharma US IncMyrbetriq$59$11,38514 claims
Boehringer IngelheimJardiance$205$8,97713 claims
AbbVieSynthroid$949$4,33834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →